We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App




CerTest to Run ‘More than Diagnostics’ Campaign Throughout 2023

By LabMedica International staff writers
Posted on 01 Feb 2023
Print article
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)
Image: The ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future (Photo courtesy of CerTest)

The world is currently experiencing a change of era. Even as it still emerging from the SARS-CoV-2 pandemic, there are new unexpected challenges that must be met. For CerTest Biotec (Zaragoza, Spain), the recent years of the pandemic have been a turning point that have made it a better company in every sense. CerTest has demonstrated that under extreme conditions, it has the ability to work towards achieving a common goal, offer a befitting response to the extraordinary circumstances and, instill confidence among its customers, suppliers and partners.

CerTest has now announced that the company will run its campaign ‘More than Diagnostics’ throughout 2023 in acknowledgement of the transformation that it has gone through, accelerated by the COVID-19 pandemic. CerTest’s ‘More than Diagnostics’ campaign expresses the company’s ambition to continue growing and advancing towards an exciting future, with people’s health remaining its key focus.

CerTest remains optimistic about the future and is well aware of the need to sustain its efforts and to continue backing the four concepts which have defined the company right from the start - service, responsibility, confidence and research. Over the coming period, CerTest plans to employ more people, build more facilities, increase its R&D activities, and come up with more products and solutions that are better as well as more effective.

Related Links:
CerTest Biotec 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.